This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma
(T-LBL) according to modified BFM-95 regimen for acute lymphoblastic leukemia.
Drug: protocol M
Drug: maintenance therapy
Drug: Intrathecal (IT)
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02396043
Ages eligible for Study
18 Years to 65 Years
Genders eligible for Study
Accepts Healthy Volunteers
Ann Arbor stage IEto stage IVE
at lease one measurable lesion
receive no chemotherapy or radiotherapy before
Adequate renal function (eg, serum creatinine≤1.5 mg/dL and creatinine clearance ≥50 mL minute), and hepatic function (e.g, total bilirubin≤ 2 times the upper limit of normal and aspartate and alanine transaminase levels ≤ 3 times the upper limit of normal)
mismatch the inclusion criteria
systematic central nervous system involvement, previous or concomitant malignancies and any coexisting medical problems that could cause poor compliance with the study protocol.
All locations for NCT02396043
Sun Yat-sen University Cancer Center
GuangZhou, Guangdong, China, 510060
Put me in touch!
View full eligibility
Tris trial is registered with FDA with number: NCT02396043. The sponsor of the trial is Sun Yat-sen University and it is looking for 50 volunteers for the current phase.
Official trial title: Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!